Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.

Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, Lishimpi K, Nunn A, Gillespie S, Zumla A, Chintu C, Gibb DM; CHAP Trial Team.

AIDS. 2007 Jan 2;21(1):77-84.

PMID:
17148971
2.

The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children.

Walker AS, Mulenga V, Ford D, Kabamba D, Sinyinza F, Kankasa C, Chintu C, Gibb DM; CHAP Team.

Clin Infect Dis. 2007 May 15;44(10):1361-7. Epub 2007 Apr 12.

PMID:
17443476
3.

Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts.

Walter J, Mwiya M, Scott N, Kasonde P, Sinkala M, Kankasa C, Kauchali S, Aldrovandi GM, Thea DM, Kuhn L.

J Infect Dis. 2006 Dec 1;194(11):1510-8. Epub 2006 Oct 19.

4.

Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia.

Mwenya DM, Charalambous BM, Phillips PP, Mwansa JC, Batt SL, Nunn AJ, Walker S, Gibb DM, Gillespie SH.

Antimicrob Agents Chemother. 2010 Sep;54(9):3756-62. doi: 10.1128/AAC.01409-09. Epub 2010 Jun 28.

5.

The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.

Ryan M, Griffin S, Chitah B, Walker AS, Mulenga V, Kalolo D, Hawkins N, Merry C, Barry MG, Chintu C, Sculpher MJ, Gibb DM.

AIDS. 2008 Mar 30;22(6):749-57. doi: 10.1097/QAD.0b013e3282f43519.

PMID:
18356605
6.

Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial.

Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Nunn A, Chintu C, Gibb DM; CHAP Trial Team.

J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):637-45.

PMID:
16868501
7.

[Survival, clinical and biological outcomes of HIV-infected children treated by antiretroviral therapy in Africa: systematic review, 2004-2009].

Ndondoki C, Dabis F, Namale L, Becquet R, Ekouevi D, Bosse-Amani C, Arrivé E, Leroy V.

Presse Med. 2011 Jul-Aug;40(7-8):e338-57. doi: 10.1016/j.lpm.2010.11.02. Epub 2011 Feb 3. Review. French.

PMID:
21295437
8.

Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection.

Grimwade K, Swingler GH.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003508. Review.

PMID:
16437457
9.

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.

Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ.

N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.

10.

Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.

Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, Prak N, Kim C, Lak KK, Hak C, Dim B, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295-CIPRA KH001) Study Team.

Clin Infect Dis. 2014 Aug 1;59(3):435-45. doi: 10.1093/cid/ciu283. Epub 2014 Apr 23.

11.

Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children.

Walker AS, Ford D, Mulenga V, Thomason MJ, Nunn A, Chintu C, Gibb DM, Bangsberg DR.

AIDS Behav. 2009 Feb;13(1):33-41. doi: 10.1007/s10461-008-9382-4. Epub 2008 Apr 10.

PMID:
18401699
12.

Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and under.

Onakpoya IJ, Hayward G, Heneghan CJ.

Cochrane Database Syst Rev. 2015 Sep 26;(9):CD011530. doi: 10.1002/14651858.CD011530.pub2. Review.

PMID:
26408070
13.

Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Côte d'Ivoire.

Anglaret X, Messou E, Ouassa T, Toure S, Dakoury-Dogbo N, Combe P, Mahassadi A, Seyler C, N'Dri-Yoman T, Salamon R; ANRS 1203 Study Group.

AIDS. 2003 Mar 7;17(4):575-84.

PMID:
12598778
14.

Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members.

Mermin J, Lule J, Ekwaru JP, Downing R, Hughes P, Bunnell R, Malamba S, Ransom R, Kaharuza F, Coutinho A, Kigozi A, Quick R.

AIDS. 2005 Jul 1;19(10):1035-42.

PMID:
15958834
15.

Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults.

Miiro G, Todd J, Mpendo J, Watera C, Munderi P, Nakubulwa S, Kaddu I, Rutebarika D, Grosskurth H.

Trop Med Int Health. 2009 May;14(5):556-63. doi: 10.1111/j.1365-3156.2009.02259.x. Epub 2009 Mar 19.

16.

Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda.

Watera C, Todd J, Muwonge R, Whitworth J, Nakiyingi-Miiro J, Brink A, Miiro G, Antvelink L, Kamali A, French N, Mermin J.

J Acquir Immune Defic Syndr. 2006 Jul;42(3):373-8.

PMID:
16810124
17.

Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis.

Suthar AB, Granich R, Mermin J, Van Rie A.

Bull World Health Organ. 2012 Feb 1;90(2):128C-138C. doi: 10.2471/BLT.11.093260. Epub 2011 Oct 24. Review.

18.

Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal.

Maynart M, Lièvre L, Sow PS, Kony S, Gueye NF, Bassène E, Metro A, Ndoye I, Ba DS, Coulaud JP, Costagliola D; SIDAK Study Group.

J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):130-6.

PMID:
11242179
19.

Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.

Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Farrelly L, Kaganson N, Zumla A, Gillespie SH, Nunn AJ, Gibb DM; CHAP trial team.

Lancet. 2004 Nov 20-26;364(9448):1865-71.

PMID:
15555666
20.

Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa.

Pemba L, Charalambous S, von Gottberg A, Magadla B, Moloi V, Seabi O, Wasas A, Klugman KP, Chaisson RE, Fielding K, Churchyard GJ, Grant AD.

J Infect. 2008 Mar;56(3):171-8. doi: 10.1016/j.jinf.2007.12.003. Epub 2008 Feb 8.

PMID:
18262281

Supplemental Content

Support Center